Method development of metformin, saxagliptin and dapagliflozin in marketed formulation by HPLC
Keywords:
metformin, saxagliptin and dapagliflozin, simultaneous estimation, HPLC validationAbstract
The fixed-dose combination of Metformin, Saxagliptin and Dapagliflozin is a recently approved antidiabetic medication. The aim of this study was to develop a simple, rapid, sensitive, and validated isocratic reversed phase-high performance liquid chromatography (RP-HPLC) method for the simultaneous estimation of Metformin, Saxagliptin and Dapagliflozin in bulk and formulation as per ICH Guidelines. The developed method was found simple, sensitive and economical for the simultaneous estimation of MET, SXG and DGF in their tablet formulation. The validity and reliability of proposed methods were assessed by recovery studies. The recovery of added standards (80%, 100% and 120%) was found at three replicate and three concentrations level. The value of % means just close to 100, SD and % RSD are less than 2 indicate the accuracy of method. Precision was determined by repeatability and Intermediate precision of drug. Repeatability result indicates the precision under the same operating condition over short interval time. The intermediate precision study is expressed within laboratory variation on different days and analyst-to-analyst variation by different analyst. The value of SD and %RSD are less than 2 indicate the precision of method. The robustness of developed method was checked by changing in the deliberate variation in solvent.
Downloads
References
A.J. Scheen, The safety of Gliptins: updated data in 2018, Exp. Opin. Drug Saf. 17 (4) (2018) 387–405.
F.B. Hu, J.E. Manson, M.J. Stampfer, et al., Diet, lifestyle, and the risk of type 2 diabetes mellitus in women, N. Engl. J. Med. 345 (2001) 790–797.
Gaikwad D. D., Patel S. G., Waman S. A., Jadhav S. L., Dhobale S. M. Method Development and Validation of Saxagliptin Hydrochloride by RP-HPLC Method. Bul. of Env., Phar. and Li. Sc. 2020;9; (9): 22-28.
Gedawy A, Al-Salami H, Dass CR. Development and validation of a new analytical HPLC method for simultaneous determination of the antidiabetic drugs, metformin and gliclazide. J Food Drug Anal. 2019;27(1):315-22. doi: 10.1016/j.jfda.2018.06.007, PMID 30648585.
Godge RK, Shinde GS, Bhosale MS. RP-HPLC method for estimation of alogliptin and glibenclamide in synthetic mixture. Res J Pharm Technol. 2020;13(2):555-9. doi: 10.5958/0974-360X.2020.00104.3.
Gundala A. P, Koganti B. Application of quality by design approach in RP-HPLC method development for simultaneous estimation of saxagliptin and dapagliflozin in tablet dosage form. Braz J Pharm Sci. 2019;55:1-10.
Gundala Aruna, Kammuri Sree Divya and Bharathi K. Stability Indicating Rp-Hplc Method Development and Validation for Simultaneous Estimation of Saxagliptin and Dapagliflozin, EJB Pha. Sci. 2018: 5:6:501-509.
J. Tuomilehto, J. Lindström, J.G. Eriksson, Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance, N. Engl. J. Med. 344 (2001) 1343–1350.
Kant R, Bodla RB, Kapoor G, Bhutani R. Optimization of a single HPLC-PDA method for quantifying metformin, gliclazide, pioglitazone, Dapagliflozin, Empagliflozin, saxagliptin, linagliptin and Teneligliptin using central composite design. Bioorg Chem. 2019;91(January):103111. doi: 10.1016/j.bioorg.2019.103111.
Kaushal A, Singh S, Arora S, Sharma N. a Cost Effective RP-HPLC Method for Simultaneous Quantitative Analysis of saxagliptin and metformin hydrochloride. 2020;20(2):3284-91.
Kommineni V, Chowdary KPR, Prasad SVUM. Development and validation of a new HPLC method for the simultaneous estimation of Saxagliptine and dapagliflozin and its application in pharmacokinetic studies. Int Res J Pharm Sci. 2018;1(6):16-24.
Manasa M, Aanandhi VM. Stability indicating simultaneous method development and validation of dapagliflozin and saxagliptin by RP-HPLC. Res J Pharm Technol. 2021;14(2):1045-9. doi: 10.5958/0974-360X.2021.00187.6.
Mante G V, Hemke AT, Umekar MJ. RP-HPLC method for estimation of dapagliflozin from its tablet. Int J ChemTech Res. 2018;11(01):242-8.
Munde MK, Kulkarni NS, Rukhe NB, Sen DB. A comprehensive review on analytical method development and validation for SGLT-2 inhibitors by HPLC in its API and dosage form. Res J Pharm Technol. 2020;13(7):1-9. doi: 10.5958/0974-360X.2020.00616.2.
Patel D Seju and Dr. Patan Pragnesh. Analytical Approach For Development And Validation Of Stability Indicating Rp-Hplc Method For Simultaneous Estimation Of Saxagliptin And Dapagliflozin In Pharmaceutical Dosage Form. JETIR. 2018; 5;12: 611-620.
Prasanthi B., Gayathri Devi M., Madhavi Latha P. V.. Analytical Method Development And Validation For The Estimation Of Metformin And Sitagliptin In Bulk And Tablet Dosage Form By RP-HPLC. IAJPS 2018; 05 (02): 882-889.
R. Song, Mechanism of metformin: a tale of two sites, Diabetes Care 39 (2016) 187–189.
Rao Rama B, Rao VV, Venkateswarlu BS. RP-HPLC method for simultaneous estimation of dapagliflozin and saxagliptin in bulk samples. J Pharm Sci Res. 2019;11(1):254-7.
Rohini S, Nagaraju K. Analytical method development and validation for the estimation of saxagliptin and metformin by RP HPLC method. Int J Adv Res Dev. 2018;3(10):23-8.
S. Kalra, Sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology, Diabetes Ther. 5 (2) (2014) 355–366.
Shafaat Syed Wajahat, Ahmed Aejaz, Khan G. J., Anas Shaikh and Qureshi A. Absar. Analytical Method Development and Validation For Simultaneous Estimation Of Ertugliflozin And Metformin Hcl In Bulk And Pharmaceutical Dosage Form By HPLC. IJPSR, 2020; Vol. 11(1): 226-232.
Shaw J.E., Sicree R.A., Zimmet P.Z., Global estimates of the prevalence of diabetes, Diabetes Res. Clin. Pract., 2010, 87,4-14.
Sivagami B, Padmaja BR, Babu MN. A highly validated RP-HPLC method development for the simultaneous estimation of dapagliflozin and saxagliptin in tablet dosage forms. Int J Pharm Sci Drug Res. 2018;10(5):372-8. doi: 10.25004/IJPSDR.2018.100503.
Thiyagarajan Deepan, Magharla Dasaratha Dhanaraju. Stability indicating HPLC method for the simultaneous determination of dapagliflozin and saxagliptin in bulk and tablet dosage form. Curr. Issues Pharm. Med. Sci., 2018; 31; (1): 39-43.
Umbarkar RP, Mittal A, Charde MS. Validated stability-indicating assay UHPLC method for simultaneous analysis of saxagliptin and metformin in fixed-dose combinations. Biointerface Res Appl Chem. 2022; 12(3):2729-44.
Upadhyay NK, Rathore C, Sapra S, Negi P. Novel RP-HPLC method development and validation for the simultaneous estimation of saxagliptin and glimepiride. Int J Appl Pharm. 2018;10(3):151-6.
Urooj A. Development and validation of Rp-hplc method for simultaneous estimation of dapagliflozin and metformin in bulk and in synthetic mixture. World J Pharm Pharm Sci. 2017 (January):2139-50. doi: 10.20959/wjpps20177-9657.
Vaishali B. Bhamare and Dr. Charushila Bhangale. Analytical Method Development, Validation and Forced Degradation Of Dapaglipflozin By RP-HPLC. W. J. of Pha. Res. 2020;9;(12):1006-1076.
Verma MV, Patel CJ, Patel MM. Development and stability indicating HPLC method for dapagliflozin in API and pharmaceutical dosage form. Int J Appl Pharm. 2017; 9(5):33-41. doi: 10.22159/ijap.2017v9i5.19185.
Zinjad SS, Gaikwad DD. PSG, Jadhav SL. Analytical method development of saxagliptin HCl by RP-HPLC. J Drug Deliv Ther. 2019;9(4):274-8.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
